Q3 EPS Estimate for Autolus Therapeutics Lifted by Analyst

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Investment analysts at William Blair lifted their Q3 2025 earnings estimates for shares of Autolus Therapeutics in a research note issued on Monday, October 27th. William Blair analyst M. Phipps now forecasts that the company will earn ($0.18) per share for the quarter, up from their previous estimate of ($0.21). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. William Blair also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.79) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.42) EPS and FY2028 earnings at ($0.14) EPS.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company cut their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, October 20th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.12.

Autolus Therapeutics Stock Up 3.4%

NASDAQ:AUTL opened at $1.51 on Thursday. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $4.12. The firm has a 50 day moving average of $1.53 and a 200 day moving average of $1.80. The stock has a market capitalization of $401.87 million, a price-to-earnings ratio of -1.80 and a beta of 1.84.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $12.92 million.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUTL. Marex Group plc acquired a new stake in Autolus Therapeutics during the second quarter valued at $28,000. R Squared Ltd acquired a new stake in Autolus Therapeutics during the second quarter valued at $50,000. Invesco Ltd. grew its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the period. Delaney Dennis R purchased a new position in Autolus Therapeutics during the second quarter valued at $55,000. Finally, Forefront Wealth Management Inc. purchased a new position in Autolus Therapeutics during the second quarter valued at $61,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.